Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | ELANE | P08246 | 9/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10559530 | 0.84 | LMNA (0.62) | LMNAMAPTACHEALOX5POLB | |
| SCHEMBL18791204 | 0.83 | CYP3A4 (0.67) | ELANEPOLBCYP3A4 | |
| SCHEMBL15495839 | 0.83 | LMNA (0.57) | LMNAMAPTACHEALOX5POLB | |
| SCHEMBL819332 | 0.80 | LMNA (0.74) | LMNAMAPTACHEALOX5POLB | |
| SCHEMBL17585017 | 0.80 | ELANE (0.55) | ELANEMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL7922562 | 0.80 | LMNA (0.74) | LMNAMAPTACHEALOX5POLB | |
| SCHEMBL29418226 | 0.80 | LMNA (0.74) | LMNAMAPTACHEALOX5POLB | |
| SCHEMBL6024449 | 0.80 | CYP1A2 (0.53) | LMNAELANEMAPTALDH1A1KMT2A | |
| SCHEMBL21281787 | 0.80 | ELANE (0.52) | ELANECYP3A4 | |
| SCHEMBL10457691 | 0.80 | ELANE (0.56) | ELANEKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11680074-B2 | Compounds, functionalised dioxaborolane or dioxaborinane derivatives, method for preparing same and uses thereof | ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS (FR) | 2023-06-20 | — | — | US | disclosed |
| US-11680074-B2 | Compounds, functionalised dioxaborolane or dioxaborinane derivatives, method for preparing same and uses thereof | ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS (FR) | 2023-06-20 | — | — | US | disclosed |
| EP-3464300-B1 | NOVEL COMPOUNDS, FUNCTIONALISED DIOXABOROLANE OR DIOXABORINANE DERIVATIVES, METHOD FOR PREPARING SAME AND USES THEREOF | ECOLE SUPERIEURE DE PHYSIQUE ET CHIMIE IND DE LA VILLE DE PARIS (FR) | 2021-12-01 | — | — | EP | disclosed |
| US-20160074853-A1 | LIGAND, NICKEL COMPLEX COMPRISING THE LIGAND, AND REACTION USING THE NICKEL COMPLEX | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2016-03-17 | — | — | US | disclosed |
| US-20160074853-A1 | LIGAND, NICKEL COMPLEX COMPRISING THE LIGAND, AND REACTION USING THE NICKEL COMPLEX | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2016-03-17 | — | — | US | disclosed |
| US-20150266834-A1 | TRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2015-09-24 | — | — | US | disclosed |
| EP-2316831-B1 | 2-(morpholin-4-yl)pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer | NOVARTIS AG (CH) | 2013-03-06 | — | — | EP | disclosed |
| US-7820654-B2 | Pyrimidine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-10-26 | — | — | US | disclosed |
| US-7767669-B2 | Small molecule PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-08-03 | — | — | US | disclosed |
| US-20090060912-A1 | SMALL MOLECULE PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | CHIRON CORPORATION (US) | 2009-03-05 | — | — | US | disclosed |
| US-7423148-B2 | Small molecule PI 3-kinase inhibitors and methods of their use | CHIRON CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| US-20080182851-A1 | ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-07-31 | — | — | US | disclosed |
| US-5521179-A | Heterocyclic amides | ZENECA LIMITED (GB) | 1996-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160074853-A1 | LIGAND, NICKEL COMPLEX COMPRISING THE LIGAND, AND REACTION USING THE NICKEL COMPLEX | NISCH, DDT, TEC | LMNA 4621/4885ELANE 1846/4885MAPT 4289/4885 |
| US-11680074-B2 | Compounds, functionalised dioxaborolane or dioxaborinane derivatives, method for preparing same and uses thereof | RDX, XDH, NOX4 | LMNA 1743/4885ELANE 2138/4885MAPT 4464/4885 |
| US-20080182851-A1 | ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | SCD, SCD5, ACACA | LMNA 823/4885ELANE 3376/4885MAPT 2813/4885 |
| US-20150266834-A1 | TRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | PTGIS, PTGS1, PTGES | LMNA 3580/4885ELANE 3094/4885MAPT 124/4885 |
| US-20090060912-A1 | SMALL MOLECULE PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | PI4KB, AKT3, PI4KA | LMNA 2754/4885ELANE 2521/4885MAPT 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.